Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer
Authors
Smyth, LMTamura, K
Oliveira, M
Ciruelos, EM
Mayer, IA
Sablin, MP
Biganzoli, L
Ambrose, HJ
Ashton, Jack
Barnicle, A
Cashell, DD
Corcoran, C
de Bruin, EC
Foxley, A
Hauser, J
Lindemann, JPO
Maudsley, R
McEwen, R
Moschetta, M
Pass, M
Rowlands, V
Schiavon, G
Banerji, U
Scaltriti, M
Taylor, BS
Chandarlapaty, S
Baselga, J
Hyman, DM
Affiliation
Medicine, Memorial Sloan Kettering Cancer CenterIssue Date
2020
Metadata
Show full item recordCitation
Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer. Clin Cancer Res. 2020.Journal
Clinical Cancer ResearchDOI
10.1158/1078-0432.ccr-19-3953PubMed ID
32312891Additional Links
https://dx.doi.org/ 10.1158/1078-0432.ccr-19-3953Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.ccr-19-3953
Scopus Count
Collections
Related articles
- Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.
- Authors: Hu X, Zhang Q, Sun T, Xiong H, Li W, Teng Y, Lu YS, Tseng LM, Yan M, Li H, Pang D, -Chen SC, Chen W, Jiang O, Wang J, Wu X, Wang X, Zang A, Wang X, Collins JM, Fan E, Jiang L, Zeng X, Turner NC
- Issue date: 2025 May 9
- US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations.
- Authors: Dilawari A, Buturla J, Osgood C, Gao X, Chen W, Ricks TK, Schaefer T, Avasarala S, Reyes Turcu F, Pathak A, Kalavar S, Bhatnagar V, Collazo J, Rahman NA, Mixter B, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani L
- Issue date: 2024 Dec
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
- Authors: Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH
- Issue date: 2022 Jul
- BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
- Authors: Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M
- Issue date: 2019 May 1
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
- Authors: Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT
- Issue date: 2021 Feb 1